An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples